Seminarios de la Fundación Espa?ola de Reumatología最新文献_第4页

Condroitín sulfato reduce la pérdida del cartílago articular y las lesiones en el hueso subcondral 硫酸软骨素减少关节软骨的损失和软骨下骨的损伤

Seminarios de la Fundación Espa?ola de Reumatología Pub Date : 2012-12-01 DOI: 10.1016/S1577-3566(12)72137-1

Jordi Monfort-Faure

引用次数: 0

Utilidad del condroitín sulfato en el tratamiento de la artrosis de manos 硫酸软骨素在手部骨关节炎治疗中的应用

Seminarios de la Fundación Espa?ola de Reumatología Pub Date : 2012-12-01 DOI: 10.1016/S1577-3566(12)72138-3

Alejandro Olivé-Marqués

{"title":"Utilidad del condroitín sulfato en el tratamiento de la artrosis de manos","authors":"Alejandro Olivé-Marqués","doi":"10.1016/S1577-3566(12)72138-3","DOIUrl":"10.1016/S1577-3566(12)72138-3","url":null,"abstract":"<div><p>Treatment of hand ostearthritis is currently insufficient. Education programs, acetanomiphen, nonsteroidal anti-inflammatory drugs and capsaicin are used. There is lack of studies concerning chondrointin sulphate in the treatment of hand osteoarthritis.</p><p>The present study examines the usefulness of chondroitin sulphate in the treatment of hand osteoarthritis.</p><p>The study was randomized, double blind and placebo controlled. All patients fulfilled the diagnostic criteria of the American College of Rheumatology. One hundred sixty patients were recruited and randomized in 2 arms : 82 patients received placebo and 80 patients chondroitin sulphate. Primary end points were visual analogue scale and functional index. Secondary end points were hand strength, morning stiffness, investigator's opinion and weekly consume of acatanomiphen. Duration of the study was 6 months. At the end of the study there was a significant difference between the group treated with chondroitin sulphate and placebo in visual analogue scale (VAS 2.14; p=0.008),functional index (FIHOA:2.14; p=0.008), morning stiffness (difference 5’1 minutes; p=0.031) and investigators opinion (44% versus 33%; p=0.043). Adverse reactions were similar between both groups.</p><p>The authors emphasize the usefulness of chondroitin sulphate in the treatment of hand osteoarthritis and the safety profile of the drug</p></div>","PeriodicalId":101152,"journal":{"name":"Seminarios de la Fundación Espa?ola de Reumatología","volume":"13 ","pages":"Pages 25-27"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1577-3566(12)72138-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115070802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artrosis y comorbilidad cardiovascular 骨关节炎和心血管共病

Seminarios de la Fundación Espa?ola de Reumatología Pub Date : 2012-12-01 DOI: 10.1016/S1577-3566(12)72139-5

Cristóbal Orellana, Joan Calvet

{"title":"Artrosis y comorbilidad cardiovascular","authors":"Cristóbal Orellana, Joan Calvet","doi":"10.1016/S1577-3566(12)72139-5","DOIUrl":"10.1016/S1577-3566(12)72139-5","url":null,"abstract":"<div><p>The relationship between osteoartritis (OA) and metabolic disorders, such as diabetes or dyslipemia, and cardiovascular comorbidity has been well established in epidemiologic studies, especially in the case of knee OA. This association has also been observed between OA and the metabolic syndrome, which is a major risk factor for cardiovascular disease. The functional disability resulting from advanced joint disease as well as Joint overload related to obesity and the the frequent coexistence of cardiovascular morbidity in an aging population were the major factors though to be involved. However, this ssociation has also been found in younger patients and in hand OA, thus pointing to the possible existence of additional factors not related to joint overload, diasbility or age. In recent years several metabolic and inflammatory factors present both in OA and in the different cardiovascular risk factors have been implicated, such as lipid homeostasis dysregulation and especially the activity of adipocytokines, cytokines released from adipose tissue with a synergistic action with proinflammatory cytokines and other inflammatory mediators. The evidence for this associations and the possible mechanisms are reviewed.</p></div>","PeriodicalId":101152,"journal":{"name":"Seminarios de la Fundación Espa?ola de Reumatología","volume":"13 ","pages":"Pages 28-32"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1577-3566(12)72139-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122838951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comentarios sobre los criterios OARSI en artrosis de rodilla 膝关节骨关节炎OARSI标准综述

Seminarios de la Fundación Espa?ola de Reumatología Pub Date : 2012-12-01 DOI: 10.1016/S1577-3566(12)72136-X

Ingrid Möller

引用次数: 2

Conclusiones del documento SER sobre el tratamiento farmacológico de la artrosis de rodilla SER论文关于膝关节药物治疗的结论

Seminarios de la Fundación Espa?ola de Reumatología Pub Date : 2012-12-01 DOI: 10.1016/S1577-3566(12)72135-8

Cristóbal Orellana

引用次数: 0

Guías y recomendaciones para el diagnóstico y tratamiento de la artrosis: en busca del consenso 骨关节炎诊断和治疗的指南和建议:寻求共识

Seminarios de la Fundación Espa?ola de Reumatología Pub Date : 2012-12-01 DOI: 10.1016/S1577-3566(12)72134-6

Pere Benito-Ruiz

{"title":"Guías y recomendaciones para el diagnóstico y tratamiento de la artrosis: en busca del consenso","authors":"Pere Benito-Ruiz","doi":"10.1016/S1577-3566(12)72134-6","DOIUrl":"10.1016/S1577-3566(12)72134-6","url":null,"abstract":"<div><p>Osteoarthritis cannot be considered a single disease but rather a heterogeneous group of ailments with similar clinical symptoms and analogous radiological and pathological changes, which makes it difficult to establish uniform recommendations for them all.</p><p>Given this disparity it is necessary to establish recommendations that will make a series of criteria available for professionals in order to unify their attitudes.</p><p>The American College of Rheumatology (ACR) established the first criteria for the classification of osteoarthritis of the hand, hip and knee, but it was not until 2000 that its recommendations for the medical treatment of osteoarthritis of the hip and knee were published, followed by the European recommendations in 2001, subsequently revised in 2003 and 2005. In 2007 the recommendations for the treatment of osteoarthritis of the hands were published. Finally, in 2008, the Osteoarthritis Research Society International (OARSI) recommendations for the treatment of osteoarthritis of the hip and knee, result of consensus between European League Against Rheumatism (EULAR) and ACR, were published.</p><p>A second review of new evidence gathered from January 2006, when the OARSI recommendations were made, until January 2009, showed variations in the range of the effect of the different forms of treatment. Adherence to the recommendations is in general low, and it seems necessary to create strategies to make it easier for professionals to follow the recommendations, as well as to design and conduct clinical trials, which meet a set of minimum parameters, sufficiently specific and sensitive, in order to assess their effect on the disease. Only by regularly updating this knowledge can we help improve our clinical practice, as long as strategies are developed to facilitate adherence to the recommendations from the professionals involved.</p></div>","PeriodicalId":101152,"journal":{"name":"Seminarios de la Fundación Espa?ola de Reumatología","volume":"13 ","pages":"Pages 3-8"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1577-3566(12)72134-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124636025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

La artrosis: nuevos horizontes 骨关节炎:新视野

Seminarios de la Fundación Espa?ola de Reumatología Pub Date : 2012-12-01 DOI: 10.1016/S1577-3566(12)72133-4

Alejandro Olivé-Marqués

引用次数: 0

¿Se deben tratar preventivamente los pacientes asintomáticos con anticuerpos antifosfolípidos? 无症状患者是否应使用抗磷脂抗体进行预防性治疗?

Seminarios de la Fundación Espa?ola de Reumatología Pub Date : 2012-10-01 DOI: 10.1016/j.semreu.2012.09.001

Paula Estrada, Carmen Gómez-Vaquero, Laura López Vives, Javier Narváez

{"title":"¿Se deben tratar preventivamente los pacientes asintomáticos con anticuerpos antifosfolípidos?","authors":"Paula Estrada, Carmen Gómez-Vaquero, Laura López Vives, Javier Narváez","doi":"10.1016/j.semreu.2012.09.001","DOIUrl":"10.1016/j.semreu.2012.09.001","url":null,"abstract":"<div><p>The prevalence of antiphospholipid antibodies (aPL) in the general population is 1%. Not all asymptomatic patients with aPL antibodies have the same risk for thrombosis, and consequently routine prophylaxis with acetylsalicylic acid (ASA) is not justified in terms of risk-benefit in all asymptomatic carriers. Based on current evidence, primary prevention is indicated only in high-risk groups including the following: a)in patients with anticardiolipin antibodies (aCL) at persistently high titers, repeatedly positive lupus anticoagulant (LA) or aCL positivity, LA and anti-beta2 glycoprotein I (triple positivity) regardless of titer; b)in situations of high thrombotic risk due to the concomitant presence of other thrombotic risk factors (hypertension, immobilization, surgery, etc.); c) in the presence of a systemic autoimmune disease, particularly systemic lupus erythematosus, and d) during pregnancy. Prophylactic treatment in these patients is based on the use of ASA. In specific situations, low-molecular-weight heparin and hydroxychloroquine are also useful.</p></div>","PeriodicalId":101152,"journal":{"name":"Seminarios de la Fundación Espa?ola de Reumatología","volume":"13 4","pages":"Pages 147-151"},"PeriodicalIF":0.0,"publicationDate":"2012-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.semreu.2012.09.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129256477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Pie diabético 派糖尿病

Seminarios de la Fundación Espa?ola de Reumatología Pub Date : 2012-10-01 DOI: 10.1016/j.semreu.2012.06.003

Emilia Gómez Hoyos , A. Esther Levy , Angel Díaz Perez , Martín Cuesta Hernández , Carmen Montañez Zorrilla , Alfonso L. Calle Pascual

引用次数: 2

Metatarsalgia 跖骨痛

Seminarios de la Fundación Espa?ola de Reumatología Pub Date : 2012-10-01 DOI: 10.1016/j.semreu.2012.07.002

Jesús Rodríguez Moreno

引用次数: 0